Chapter 29. Oral Antidiabetic Agents

  1. Richard I. G. Holt MA, MB BChir, PhD, FRCP, FHEA Professor in Diabetes & Endocrinology3,
  2. Clive S. Cockram MB BS, BSc, MD (Lond), FRCP, FRACP, FHKAM (Med) Emeritus Professor of Medicine4,
  3. Allan Flyvbjerg MD, DMSc Professor of Clinical Endocrinology Chair5 and
  4. Barry J. Goldstein MD, PhD, FACP, FACE Therapeutic Area Head Vice President6
  1. Clifford J. Bailey PhD, FRCP(Edin), FRCPath Professor1 and
  2. Andrew J. Krentz MD, FRCP2

Published Online: 9 JUL 2010

DOI: 10.1002/9781444324808.ch29

Textbook of Diabetes, Fourth Edition

Textbook of Diabetes, Fourth Edition

How to Cite

Bailey, C. J. and Krentz, A. J. (2010) Oral Antidiabetic Agents, in Textbook of Diabetes, Fourth Edition (eds R. I. G. Holt, C. S. Cockram, A. Flyvbjerg and B. J. Goldstein), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444324808.ch29

Editor Information

  1. 3

    Developmental Origins of Health and Disease Division, University of Southampton School of Medicine, Southampton, UK

  2. 4

    Chinese University of Hong Kong, Hong Kong SAR, People's Republic of China

  3. 5

    Department of Endocrinology and Internal Medicine, The Medical Research Laboratories, Aarhus University Hospital – Aarhus University, Aarhus, Denmark

  4. 6

    Clinical Research, Metabolism Merck Research Laboratories Rahway, NJ, USA

Author Information

  1. 1

    School of Life and Health Sciences, Aston University, Birmingham, UK

  2. 2

    Formerly Southampton University Hospitals NHS Trust, Southampton, UK

Publication History

  1. Published Online: 9 JUL 2010
  2. Published Print: 9 JUL 2010

ISBN Information

Print ISBN: 9781405191814

Online ISBN: 9781444324808

SEARCH

Keywords:

  • Pathophysiologic considerations;
  • UK Prospective Diabetes Study (UKPDS);
  • Action to Control Cardiovascular Risk in Diabetes (ACCORD);
  • Guidelines and algorithms;
  • Meglitinides (short-acting prandial insulin releasers);
  • α-Glucosidase inhibitors;
  • Fixed-dose combinations;
  • Antiobesity therapies;
  • maturity - onset diabetes of the young (MODY);
  • peroxisome proliferator - activated receptor (PPAR)

Summary

This chapter contains sections titled:

  • Introduction

  • Pathophysiologic considerations

  • Guidelines and algorithms

  • Biguanides

  • Sulfonylureas

  • Meglitinides (short-acting prandial insulin releasers)

  • Thiazolidinediones

  • Gliptins

  • α-Glucosidase inhibitors

  • Antiobesity therapies

  • Fixed-dose combinations

  • Conclusions

  • References